Cargando…
Interim analysis of the COSA (COVID-19 patients treated with the Seraph(®) 100 Microbind(®) Affinity filter) registry
BACKGROUND: The Seraph(®) 100 Microbind(®) Affinity Blood Filter is a haemoperfusion device that is licensed for the reduction of pathogens, including several viruses, in the blood. It received Emergency Use Authorization for the treatment of severe coronavirus disease 2019 (COVID-19) by the Food an...
Autores principales: | Schmidt, Julius J, Borchina, Dan Nicolae, van't Klooster, Mariet, Bulhan-Soki, Khalida, Okioma, Reuben, Herbst, Larissa, Rodríguez, Diego Sandoval, Premužić, Vedran, Büttner, Stefan, Bader, Birgit, Serednicki, Wojciech, Zasada, Ewa, Schmitz, Michael, Quabach, Ralf A, Hrincheva, Maria, Fühner, Thomas, Kielstein, Jan T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689741/ https://www.ncbi.nlm.nih.gov/pubmed/34875087 http://dx.doi.org/10.1093/ndt/gfab347 |
Ejemplares similares
-
Hemofiltration with the Seraph(®) 100 Microbind(®) Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients
por: Kielstein, Jan T., et al.
Publicado: (2021) -
Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
por: Pape, Anke, et al.
Publicado: (2021) -
In vitro elimination of anti-infective drugs by the Seraph(®) 100 Microbind(®) affinity blood filter
por: Schmidt, Julius J, et al.
Publicado: (2020) -
Staphylococcus aureus binding to Seraph(®) 100 Microbind(®) Affinity Filter: Effects of surface protein expression and treatment duration
por: Seffer, Malin-Theres, et al.
Publicado: (2023) -
Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study
por: Eden, Gabriele, et al.
Publicado: (2022)